Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs Inc. (BIOA) is a clinical-stage biopharmaceutical company developing therapies targeting aging biology to treat metabolic diseases and neuroinflammation. This page provides investors and industry professionals with verified updates on the company’s progress, including clinical trial developments, strategic partnerships, and regulatory milestones.
Access the latest press releases and news articles covering BIOA’s pipeline advancements, such as its apelin receptor agonist Azelaprag (BGE-105) for obesity and BGE-100 for neuroinflammatory conditions. Stay informed about preclinical research outcomes, financial disclosures, and collaborations shaping the company’s innovative approach to age-related diseases.
Key updates include trial phase results, FDA communications, and analyses of BIOA’s unique position in the competitive biopharma landscape. Bookmark this page for real-time insights into how BioAge Labs leverages aging biology to address complex health challenges.
BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.
Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.
The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.
BioAge Labs (NASDAQ: BIOA), a clinical-stage biotech company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major upcoming investor conferences. The company's leadership, including CEO and co-founder Dr. Kristen Fortney and CFO Dr. Dov Goldstein, will attend:
• The Jefferies Global Healthcare Conference in New York (June 3-5, 2025) for one-on-one meetings
• The Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11, 2025), featuring a fireside chat on June 9 at 3:20 PM EDT and one-on-one meetings. A webcast will be available and archived for 30 days on the company's investor relations website.
BioArctic AB (BIOA) announced that its partner Eisai projects Leqembi® sales to reach JPY 76.5 billion (approximately SEK 5.1 billion) for fiscal year 2025 (April 2025 - March 2026). This represents a 73% growth compared to the previous year and is expected to generate around SEK 510 M in royalty for BioArctic.
Eisai leads Leqembi's development and regulatory submissions globally, with both Eisai and Biogen co-commercializing the product. BioArctic maintains rights to commercialize Leqembi in the Nordic region in partnership with Eisai, and both companies are preparing for joint commercialization in the region.
BioArctic AB (Nasdaq Stockholm: BIOA B) has announced it will release its Q1 2025 financial report on Wednesday, May 21, 2025, at 08:00 CET. Following the report's publication, the company will host an audiocast with teleconference in English at 09:30 CET.
CEO Gunilla Osswald and CFO Anders Martin-Löf will present the quarterly results and conduct a Q&A session. Participants can join via webcast or teleconference, with options for submitting questions either in writing through the webcast or verbally via the teleconference. The presentation will later be available on-demand through BioArctic's corporate website.